SoftBank has announced a joint venture with Tempus AI, a company that develops AI-powered tools for interpreting health screening data. The purpose of this collaboration is to expand into the health technology business in Japan.
In the terms of the joint venture agreement, SoftBank and Tempus AI will each invest 15 billion yen to establish a company called SB TEMPUS. This new company will leverage the health technology and AI services already provided by Tempus AI in the United States, and extend them to customers in Japan.
Masayoshi Son, the CEO of SoftBank, revealed that currently only 1% of patients in Japan undergo genetic data screening for treatment purposes, while in the United States, the number stands at 30%. The goal of SB TEMPUS is to increase the screening rate in Japan to match that of the United States. This initiative is beneficial for treating a wide range of diseases, from cancer to neurological disorders and more.
Source: SoftBank and TechCrunch
TLDR: SoftBank partners with Tempus AI to venture into the health technology sector in Japan, aiming to increase the genetic data screening rate for treatment purposes.
Leave a Comment